These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22248721)

  • 21. New-generation platinum agents for solid tumors.
    Shah N; Dizon DS
    Future Oncol; 2009 Feb; 5(1):33-42. PubMed ID: 19243296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of chemotherapy efficacy in breast cancer.
    González-Neira A
    Pharmacogenomics; 2012 Apr; 13(6):677-90. PubMed ID: 22515610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapeutics in metastatic bladder cancer.
    Lekas A; Papathomas TG; Papatsoris AG; Deliveliotis C; Lazaris AC
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1889-99. PubMed ID: 19012504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy.
    Zhang J; Fan M; Xie J; Wang Z; Wang B; Zhang S; Wang L; Cao J; Tao Z; Li T; Hu X
    Oncotarget; 2015 Dec; 6(40):43135-43. PubMed ID: 26447756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of metastatic breast cancer: second line and beyond.
    Roché H; Vahdat LT
    Ann Oncol; 2011 May; 22(5):1000-1010. PubMed ID: 20966181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which patients with early-stage triple-negative breast cancer should receive a platinum?
    Sikov WM
    Clin Adv Hematol Oncol; 2017 Jul; 15(7):510-514. PubMed ID: 28749912
    [No Abstract]   [Full Text] [Related]  

  • 27. Chemotherapy with Platinum Compounds: Current Status and Future Directions. Volume 3: Dosing, Head and Neck Cancer, Genitourinary Cancer, Pediatric Cancer, Tumor of Unknown Origin, Dose Intensity, Future Directions. Kona, Hawaii, February 24-28, 1993.
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):1-118. PubMed ID: 7992060
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel insights in clinical trials with preoperative systemic therapy for primary breast cancer.
    Toi M; Bando H; Chow LW
    Biomed Pharmacother; 2004 Nov; 58(9):531-5. PubMed ID: 15599986
    [No Abstract]   [Full Text] [Related]  

  • 29. Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer.
    Maugeri-Saccà M; Barba M; Vici P; Pizzuti L; Sergi D; Catenaro T; Di Lauro L; Mottolese M; Santini D; Milella M; De Maria R
    Crit Rev Oncol Hematol; 2016 Oct; 106():132-42. PubMed ID: 27637358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results and the prospects of use of the new chemical preparation polyplatillene with antineoplastic and antiviral properties].
    Shalimov SA; Keisevich LV; Vokchenskova II; Iatsenko LD; Maídanevich NN; Korchevaia LM
    Klin Khir; 1997; (2):9-12. PubMed ID: 9424300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
    Vaishampayan U; Shevrin D; Stein M; Heilbrun L; Land S; Stark K; Li J; Dickow B; Heath E; Smith D; Fontana J
    Urology; 2015 Dec; 86(6):1206-11. PubMed ID: 26375845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck.
    Psyrri A; Rampias T; Vermorken JB
    Ann Oncol; 2014 Nov; 25(11):2101-2115. PubMed ID: 25057165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
    Shiah HS; Chen CY; Dai CY; Hsiao CF; Lin YJ; Su WC; Chang JY; Whang-Peng J; Lin PW; Huang JD; Chen LT
    Aliment Pharmacol Ther; 2013 Jan; 37(1):62-73. PubMed ID: 23134470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
    Huang X; Chau CH; Figg WD
    J Hematol Oncol; 2012 Jul; 5():35. PubMed ID: 22747660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
    Carey LA; Rugo HS; Marcom PK; Mayer EL; Esteva FJ; Ma CX; Liu MC; Storniolo AM; Rimawi MF; Forero-Torres A; Wolff AC; Hobday TJ; Ivanova A; Chiu WK; Ferraro M; Burrows E; Bernard PS; Hoadley KA; Perou CM; Winer EP
    J Clin Oncol; 2012 Jul; 30(21):2615-23. PubMed ID: 22665533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
    von Minckwitz G; Schneeweiss A; Loibl S; Salat C; Denkert C; Rezai M; Blohmer JU; Jackisch C; Paepke S; Gerber B; Zahm DM; Kümmel S; Eidtmann H; Klare P; Huober J; Costa S; Tesch H; Hanusch C; Hilfrich J; Khandan F; Fasching PA; Sinn BV; Engels K; Mehta K; Nekljudova V; Untch M
    Lancet Oncol; 2014 Jun; 15(7):747-56. PubMed ID: 24794243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxicity of bismuth(III) dithiocarbamate derivatives by promoting a mitochondrial-dependent apoptotic pathway and suppressing MCF-7 breast adenocarcinoma cell invasion.
    Chan PF; Ang KP; Hamid RA
    J Biol Inorg Chem; 2024 Mar; 29(2):217-241. PubMed ID: 38369679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of biological behavior of lacrimal gland adenoid cystic carcinoma with high-grade transformation cells.
    Zhang CL; Zhu LM; Liu X; Jiang MX; Lin TT; He YJ
    Int J Ophthalmol; 2023; 16(2):163-171. PubMed ID: 36816203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymeric Micelles for Breast Cancer Therapy: Recent Updates, Clinical Translation and Regulatory Considerations.
    Junnuthula V; Kolimi P; Nyavanandi D; Sampathi S; Vora LK; Dyawanapelly S
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.